Sun Pharma gets US FDA nod for its specialty psoriasis drug Ilumya
Analysts expect the company to launch the drug in next three months with a peak sale potential of USD 300 million.
Read MoreAnalysts expect the company to launch the drug in next three months with a peak sale potential of USD 300 million.
Read More